CellaVision AB (publ) (CEVI.ST)
SEK 222.0
(2.07%)
SEK 222.0
(2.07%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 207.24 Million SEK | 4.69% |
| 2022 | 190.86 Million SEK | -1.41% |
| 2021 | 193.6 Million SEK | 31.87% |
| 2020 | 124.59 Million SEK | -2.69% |
| 2019 | 150.87 Million SEK | 26.71% |
| 2018 | 113.83 Million SEK | 20.33% |
| 2017 | 98.79 Million SEK | 17.7% |
| 2016 | 75.47 Million SEK | 14.96% |
| 2015 | 73.12 Million SEK | 28.59% |
| 2014 | 44.25 Million SEK | 67.29% |
| 2013 | 27.04 Million SEK | 27.44% |
| 2012 | 26.67 Million SEK | 41.05% |
| 2011 | 25.34 Million SEK | 35.6% |
| 2010 | 20.09 Million SEK | -5.71% |
| 2009 | 14.77 Million SEK | 7.6% |
| 2008 | 13.74 Million SEK | 304.09% |
| 2007 | 3.4 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 59.7 Million SEK | 17.14% |
| 2024 Q1 | 40.49 Million SEK | -32.32% |
| 2024 Q3 | 39.49 Million SEK | -13.57% |
| 2023 Q4 | 70.78 Million SEK | 110.32% |
| 2023 Q2 | 48.18 Million SEK | 85.03% |
| 2023 FY | - SEK | 4.69% |
| 2023 Q1 | 26.04 Million SEK | -9.48% |
| 2023 Q3 | 33.65 Million SEK | -30.14% |
| 2022 Q4 | 28.76 Million SEK | 63.5% |
| 2022 FY | - SEK | -1.41% |
| 2022 Q1 | 51.49 Million SEK | 9.29% |
| 2022 Q2 | 52.91 Million SEK | 2.74% |
| 2022 Q3 | 17.59 Million SEK | -66.75% |
| 2021 Q2 | 40.36 Million SEK | 4.89% |
| 2021 Q4 | 47.12 Million SEK | 37.77% |
| 2021 Q1 | 38.48 Million SEK | 52.16% |
| 2021 FY | - SEK | 31.87% |
| 2021 Q3 | 34.2 Million SEK | -15.26% |
| 2020 Q1 | 34.13 Million SEK | -0.09% |
| 2020 Q4 | 25.29 Million SEK | 27.01% |
| 2020 FY | - SEK | -2.69% |
| 2020 Q3 | 19.91 Million SEK | -43.81% |
| 2020 Q2 | 35.43 Million SEK | 3.82% |
| 2019 Q2 | 38.64 Million SEK | 8.97% |
| 2019 Q3 | 22.43 Million SEK | -41.95% |
| 2019 Q1 | 35.46 Million SEK | 0.71% |
| 2019 FY | - SEK | 26.71% |
| 2019 Q4 | 34.16 Million SEK | 52.29% |
| 2018 Q1 | 23.84 Million SEK | 19.9% |
| 2018 FY | - SEK | 20.33% |
| 2018 Q4 | 35.21 Million SEK | 67.51% |
| 2018 Q3 | 21.02 Million SEK | -34.75% |
| 2018 Q2 | 32.22 Million SEK | 35.15% |
| 2017 Q4 | 19.88 Million SEK | 84.73% |
| 2017 Q1 | 34.8 Million SEK | 73.89% |
| 2017 Q2 | 25.04 Million SEK | -28.06% |
| 2017 Q3 | 10.76 Million SEK | -57.01% |
| 2017 FY | - SEK | 17.7% |
| 2016 Q4 | 20.01 Million SEK | 0.58% |
| 2016 FY | - SEK | 14.96% |
| 2016 Q2 | 21.1 Million SEK | 42.72% |
| 2016 Q3 | 19.9 Million SEK | -5.7% |
| 2016 Q1 | 14.78 Million SEK | -5.07% |
| 2015 Q4 | 15.57 Million SEK | -49.38% |
| 2015 Q3 | 30.77 Million SEK | 267.29% |
| 2015 Q2 | 8.37 Million SEK | -22.65% |
| 2015 FY | - SEK | 28.59% |
| 2015 Q1 | 10.83 Million SEK | -35.81% |
| 2014 Q1 | 7.57 Million SEK | -49.44% |
| 2014 FY | - SEK | 67.29% |
| 2014 Q4 | 16.87 Million SEK | 112.17% |
| 2014 Q3 | 7.95 Million SEK | -30.83% |
| 2014 Q2 | 11.49 Million SEK | 51.7% |
| 2013 Q2 | -326 Thousand SEK | 46.29% |
| 2013 Q3 | 10.95 Million SEK | 3460.43% |
| 2013 Q4 | 14.99 Million SEK | 36.84% |
| 2013 FY | - SEK | 27.44% |
| 2013 Q1 | -607 Thousand SEK | -111.72% |
| 2012 Q4 | 5.18 Million SEK | 30.09% |
| 2012 Q1 | 5.36 Million SEK | -33.49% |
| 2012 Q2 | 4.54 Million SEK | -15.19% |
| 2012 Q3 | 3.98 Million SEK | -12.41% |
| 2012 FY | - SEK | 41.05% |
| 2011 Q3 | 3.72 Million SEK | -19.87% |
| 2011 FY | - SEK | 35.6% |
| 2011 Q4 | 8.05 Million SEK | 116.23% |
| 2011 Q1 | 2.47 Million SEK | -72.77% |
| 2011 Q2 | 4.65 Million SEK | 87.84% |
| 2010 Q2 | 7.1 Million SEK | 260.13% |
| 2010 Q3 | 2.18 Million SEK | -69.22% |
| 2010 Q1 | -4.43 Million SEK | -159.29% |
| 2010 FY | - SEK | -5.71% |
| 2010 Q4 | 9.09 Million SEK | 315.78% |
| 2009 Q3 | 5.47 Million SEK | 470.59% |
| 2009 Q1 | 865 Thousand SEK | -88.09% |
| 2009 Q4 | 7.48 Million SEK | 36.75% |
| 2009 Q2 | 959 Thousand SEK | 10.87% |
| 2009 FY | - SEK | 7.6% |
| 2008 FY | - SEK | 304.09% |
| 2008 Q2 | 1.51 Million SEK | 0.0% |
| 2008 Q3 | 3.59 Million SEK | 136.63% |
| 2008 Q4 | 7.26 Million SEK | 102.2% |
| 2007 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 368.724% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 49.686% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 49.686% |
| Arcoma AB | 6.24 Million SEK | -3216.981% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 330.318% |
| BICO Group AB (publ) | 322.3 Million SEK | 35.698% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | -214.108% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 402.963% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | 841.671% |
| C-Rad AB (publ) | 48.9 Million SEK | -323.779% |
| Duearity AB (publ) | -24.77 Million SEK | 936.374% |
| Dignitana AB (publ) | -264 Thousand SEK | 78601.894% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 336.311% |
| Getinge AB (publ) | 5.92 Billion SEK | 96.505% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 408.171% |
| Iconovo AB (publ) | -35.33 Million SEK | 686.507% |
| Integrum AB (publ) | 8.76 Million SEK | -2265.398% |
| Luxbright AB (publ) | -23.86 Million SEK | 968.342% |
| Mentice AB (publ) | 28.87 Million SEK | -617.781% |
| OssDsign AB (publ) | -122.02 Million SEK | 269.844% |
| Paxman AB (publ) | 31.22 Million SEK | -563.63% |
| Promimic AB (publ) | -3.68 Million SEK | 5725.544% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 237.7% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 499.863% |
| ScandiDos AB (publ) | -13.35 Million SEK | 1651.7% |
| Sectra AB (publ) | 615.06 Million SEK | 66.305% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 501.062% |
| Senzime AB (publ) | -118.82 Million SEK | 274.415% |
| SpectraCure AB (publ) | -20.96 Million SEK | 1088.34% |
| Stille AB | 56.04 Million SEK | -269.81% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 106.507% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | -63.734% |